Skip to main content

Table 2 Incidence of AF by occurrence of elevated NT-proBNP and frequent supraventricular arrhythmias

From: Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study

N = 373

Subjects

Incident AF cases

Incidence rate (per 1000 person-years)

Model 1 h (95%CI)

Model 2 h (95%CI)

NT-proBNP and SVEs

 Non-elevated NT-proBNP, infrequent SVEs

220

35

9.49

Ref

Ref

 Elevated NT-proBNP, infrequent SVEs

59

12

15.07

1.45 (0.75, 2.80)†

1.52 (0.76, 3.05)†

 Non-elevated NT-proBNP, frequent SVEs

60

22

25.30

2.48 (1.45, 4.26)

2.32 (1.33, 4.06)†

 Elevated NT-proBNP, frequent SVEs

34

19

47.05

4.19 (2.30, 7.65)

4.61 (2.45, 8.69)

Interaction NT-proBNP * SVEs

   

P = 0.740

P = 0.582

NT-proBNP and SVTs

 Non-elevated NT-proBNP, infrequent SVTs

214

31

8.68

Ref

Ref

 Elevated NT-proBNP, infrequent SVTs

61

16

20.24

1.99 (1.08, 3.67)

2.03 (1.07, 3.87)‡

 Non-elevated NT-proBNP, frequent SVTs

66

26

26.08

2.52 (1.48, 4.29)

2.26 (1.30, 3.95)

 Elevated NT-proBNP, frequent SVTs

32

15

36.66

3.55 (1.88, 6.70)

4.46 (2.24, 8.88)

Interaction NT-proBNP *SVTs

   

P = 0.443

P = 0.945

NT-proBNP and SVA

 Non-elevated NT-proBNP, non-elevated SVA

195

28

8.54

Ref

Ref

 Elevated NT-proBNP, non-elevated SVA

53

12

17.11

1.74 (0.88, 3.44)§

1.76 (0.86, 3.62)§

 Non-elevated NT-proBNP, elevated SVA

85

29

22.63

2.23 (1.32, 3.79)

2.10 (1.21, 3.65)§

 Elevated NT-proBNP, elevated SVA

40

19

38.10

3.65 (1.98, 6.73)

4.33 (2.26, 8.31)

Interaction NT-proBNP *SVA

   

P = 0.894

P = 0.740

  1. Model 1: age, sex adjusted (n = 373)
  2. Model 2: Model 1 + smoking status + anti-hypertension medications + systolic blood pressure + LDL + log of HOMA-IR + height + weight (n = 364)
  3. Frequent SVEs, SVTs, and elevated NT-proBNP were defined as the top quartile, corresponding to > 129.18 SVEs/24 h, 3.06 SVTs/24 h and 32.80 pg/ml NT-proBNP, respectively; elevated SVA was defined as frequent SVEs or SVTs
  4. AF atrial fibrillation, NT-proBNP N terminal pro B type natriuretic peptide, SVEs supraventricular extrasystoles, SVTs supraventricular tachycardias, SVA supraventricular activity
  5. †P < 0.05 when compared to group with elevated NT-proBNP and frequent SVEs
  6. ‡P < 0.05 when compared to group with elevated NT-proBNP and frequent SVTs
  7. §P < 0.05 when compared to group with elevated NT-proBNP and elevated SVA